The FDA rejected ivonescimab, a PD-1 x VEGF treatment developed by Summit Therapeutics and Akeso, citing the lack of a survival benefit despite evidence of slowing disease progression. The agency concluded that the absence of improved overall survival undermined the drug’s benefit-risk profile for approval. The rejection is a regulatory setback for Summit’s path outside China and underscores the threshold agencies apply to confirm meaningful survival outcomes. It also comes after leadership changes reported by the company, raising near-term uncertainty about trial follow-through and development strategy. Biopharma stakeholders will watch for whether Summit revises the program, seeks alternate endpoints, or reallocates resources to other assets after the negative FDA action.
Get the Daily Brief